Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Metastatic Breast Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

9 recruiting trials for Metastatic Breast Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 9 Metastatic Breast Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 33% (2 studies); the largest phase groups are Phase 1 / Phase 2: 2, Phase 1: 2, Phase 2: 1, Phase 3: 1.

Research is led by Institut Cancerologie de l'Ouest (1), Mayo Clinic (1), H. Lee Moffitt Cancer Center and Research Institute (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Trastuzumab deruxtecan (drug, 2 trials), followed by Fulvestrant, Ribociclib.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
9
Total Trials
9
Recruiting Now
1
Phase 3 Trials
9
Sponsors

Track Metastatic Breast Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06962163

Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients

Triple-negative breast cancer (TNBC) is a particularly aggressive type of breast cancer that is difficult to treat. Unlike other forms of breast cancer, TNBC tends to relapse...

Sponsor: Institut Cancerologie de l'OuestEnrolling: 121 location
RECRUITINGNCT06055881

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in...

Sponsor: Mayo ClinicEnrolling: 452 locations
RECRUITINGPhase 2NCT06409390

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 151 location
RECRUITINGPhase 1 / Phase 2NCT06202261

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy....

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Enrolling: 1542 locations
RECRUITINGNCT06904625

Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or...

This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or...

Sponsor: Institut Claudius RegaudEnrolling: 541 location
RECRUITINGPhase 1NCT06625775

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in...

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Enrolling: 39220 locations
RECRUITINGPhase 1NCT06533332

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Sponsor: EtiraRx Australia Pty LtdEnrolling: 365 locations
RECRUITINGPhase 3NCT05796973

Measuring Oncological Value of Exercise and Statin

The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney,...

Sponsor: Tampere University HospitalEnrolling: 2401 location
RECRUITINGPhase 1 / Phase 2NCT06324357

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to...

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if...

Sponsor: Boehringer IngelheimEnrolling: 76820 locations

Frequently Asked Questions

There are currently 9 clinical trials for Metastatic Breast Cancer, with 9 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Metastatic Breast Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Metastatic Breast Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.